Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.
Aviceda Therapeutics has raised $207.5M in total funding. The most recent round was Series C. The last funding was announced in January 2025.
Aviceda Therapeutics's investors include Catalio Capital Management, TCG Crossover, Blue Owl, OrbiMed, Jeito Capital.
Aviceda Therapeutics is headquartered in Cambridge, United States.
Aviceda Therapeutics is a late-stage pre-clinical biotech company developing drugs for treating glyco-immune diseases.
Aviceda Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aviceda Therapeutics — Funding & Investors." VCBacked, January 7, 2025, https://www.vcbacked.co/company/aviceda-therapeutics. Accessed September 29, 2026.
VCBacked. (2025). Aviceda Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/aviceda-therapeutics
{{cite web |title=Aviceda Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aviceda-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated